Human Peripheral Blood Macrophages, Frozen

Primary human cells, frozen

More Views

Human Peripheral Blood Macrophages, Frozen

Primary human cells, frozen

1.5 x 106 cells

Please select one of the preferences above when ordering multiple quantities

Catalog #70042
682 USD

Overview

Primary human macrophages were derived from immunomagnetically selected peripheral blood (PB) monocytes. Monocytes were cultured in RPMI 1640 Medium with 10% fetal bovine serum (FBS), M-CSF and IL-4 for 5 days to generate macrophages. PB was collected using one of the following anticoagulants: acid-citrate-dextrose (ACD), acid-citrate-dextrose solution A (ACDA), citrate-phosphate-dextrose (CPD), citrate-phosphate-double-dextrose (CP2D), or citrate-phosphate-dextrose-adenine (CPDA).

Cells were obtained using Institutional Review Board (IRB)-approved consent forms and protocols.

Certain products are only available in select territories. Please contact your local Sales representative or Product & Scientific Support at techsupport@stemcell.com for further information.
Contains:
• CryoStor® CS10
Subtype:
Frozen
Cell Type:
Monocytes; Myeloid Cells; Macrophages
Species:
Human
Cell and Tissue Source:
Peripheral Blood
Donor Status:
Normal
Purity:
The purity of macrophages is ≥ 90% for MHC class II, CD11b, CD18, and CD68 by flow cytometry.

Scientific Resources

Product Documentation

Document Type
Product Name
Catalog #
Lot #
Language

Educational Materials

(2)

Product Applications

This product is designed for use in the following research area(s) as part of the highlighted workflow stage(s). Explore these workflows to learn more about the other products we offer to support each research area.

Data and Publications

Publications

(1)
Molecular therapy : the journal of the American Society of Gene Therapy 2014 MAR

Design of a novel integration-deficient lentivector technology that incorporates genetic and posttranslational elements to target human dendritic cells.

Tareen SU et al.

Abstract

As sentinels of the immune system, dendritic cells (DCs) play an essential role in regulating cellular immune responses. One of the main challenges of developing DC-targeted therapies includes the delivery of antigen to DCs in order to promote the activation of antigen-specific effector CD8 T cells. With the goal of creating antigen-directed immunotherapeutics that can be safely administered directly to patients, Immune Design has developed a platform of novel integration-deficient lentiviral vectors that target and deliver antigen-encoding nucleic acids to human DCs. This platform, termed ID-VP02, utilizes a novel genetic variant of a Sindbis virus envelope glycoprotein with posttranslational carbohydrate modifications in combination with Vpx, a SIVmac viral accessory protein, to achieve efficient targeting and transduction of human DCs. In addition, ID-VP02 incorporates safety features in its design that include two redundant mechanisms to render ID-VP02 integration-deficient. Here, we describe the characteristics that allow ID-VP02 to specifically transduce human DCs, and the advances that ID-VP02 brings to conventional third-generation lentiviral vector design as well as demonstrate upstream production yields that will enable manufacturing feasibility studies to be conducted.
STEMCELL TECHNOLOGIES INC.’S QUALITY MANAGEMENT SYSTEM IS CERTIFIED TO ISO 13485. PRODUCTS ARE FOR RESEARCH USE ONLY AND NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED.